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Recently, the World Health Organization emphasized the
potential beneﬁt of intermittent preventive treatment in
infants (IPTi) to control malaria and ofﬁcially recommended
implementation of IPTi with sulfadoxine-pyrimethamine
(SP) in areas with moderate and high transmission, where SP
resistance is not high. As reported rebound effects make
further observation mandatory, we performed a survey of
participants of a former IPTi trial. Malariometric param-
eters were similar in the SP and the placebo group. In con-
trast, anti–Plasmodium falciparum lysate immunoglobulin G
antibody levels, a proxy measure for preceding malaria episodes,
remained lower in the SP arm. The most likely explanation is
a lower overall exposure to parasitic antigens after IPTi.
Intermittent preventive treatment in infants (IPTi) is regarded
as a promising malaria control tool, and the World Health
Organization (WHO) has recommended implementation of
IPTi with sulfadoxine-pyrimethamine (SP) in areas with mod-
erate to high malaria transmission, where parasitic resistance to
SP is not high [1]. The strategy behind IPTi is to administer full
courses of antimalarials alongside routine vaccinations of the
ExpandedProgramonImmunizationofthe WHO,regardless of
whether an infant is parasitemic [2]. A pooled analysis of 6 trials
using SP for IPTi in 4 African countries demonstrated a pro-
tective efﬁcacy of 30.3% against uncomplicated malaria, 21.3%
against anemia, and 22.9% against all-cause hospital admission
during the ﬁrst year of life [3]. In another trial from northern
Tanzania comparing various drugs for IPTi, SP failed to provide
protective efﬁcacy due to preexisting drug resistance [4].
So far, however, long-term effects of IPTi such as possible
extended efﬁcacy or rebound phenomena are largely unknown.
During the ﬁrst SP-IPTi trial in Tanzania, an extended pro-
tective antimalarial effect beyond the duration of the pharma-
cological effects was described [5]. A detailed analysis of data
from 2 studies from Ghana and Gabon suggested that SP-IPTi
works mainly through a therapeutic and prophylactic effect over
30–60 d after drug application and that sustained effects beyond
posttreatment prophylaxis might be very low [6]. In at least 3
of the SP-IPTi trials, distinct rebound effects of anemia,
high-density parasitemia, or hospital admissions were reported
[7–9]. Nevertheless, results from an extended follow-up study
in Gabon do not appear to support the concept of rebound
effects after SP-IPTi [10].
To assess the long-term effects of SP-IPTi, a cross-sectional
follow-up survey of former study participants was performed
4 yearsafter initial recruitment [7]. Anti–Plasmodiumfalciparum
lysate immunoglobulin G antibody (Pf LIgG) levels were used as
a proxy measureforthe frequencyofpreceding malaria episodes,
as has been shown to be expedient in this setting [11].
METHODS
The follow-up survey took place in the same 9 villages (Aﬁgya
Sekyere district, Ashanti region, Ghana) where the placebo-
controlled, double-blind, randomized SP-IPTi trial was per-
formed (registered at www.ClinicalTrials.gov; NCT00206739).
Recruitment in the present study was between September and
November 2007, which was 3 years after the unblinding in the
IPTi trial. In the study area, there is intense perennial malaria
transmission. Documentation of medical histories, physical
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performed following the same standard operating procedures as
described previously [7, 11]. Axillarytemperature of >38.0Co r
fever during the preceding 48 h reported by caretakers without
being asked, accompanied by asexual P. falciparum parasitemia
of.500 parasites/lL,was deﬁnedasmalaria.Bothattendanceat
outpatient clinics and admission to hospital in the time between
the original trial and the current survey were assessed by inter-
viewing caretakers and checking medical records.
Children with uncomplicated malaria were treated with ar-
tesunate (4 mg/kg/d) plus amodiaquine (10 mg/kg/d) for 3
d according to national guidelines. PfLIgG levels were measured
by enzyme-linked immunosorbent assay and expressed in rel-
ative units (RUs) as described previously [11]. Methods of
PfLIgG assessment were identical in the IPTi trial and in the
present study but were performed independently at different
time points.
Analyses were performed using Stata/IC software (version
10.0; StataCorp). Variables were compared between study arms
by a contingency test (v
2) for proportions and a nonparametric
test (Wilcoxon rank-sum) for continuous variables. The Spear-
man rank correlation test was used to correlate PfLIgG levels at
age 24 months with malaria incidence rates during the ﬁrst
2 years of life (original trial) and with Pf LIgG levels measured at
the time of the current survey. The risk of being parasite positive
at the time of the survey in dependence on rates of parasitemia
during the original trial was calculated using a bivariate logistic
regressionmodel,testing SPtreatment as a possible confounding
covariate. P values ,.05 were considered signiﬁcant.
The aim and principles of the study were explained to the
caretakers of participants, and informed consent was signed or
thumbprinted by participants’ caregivers in accordance with the
Declaration of Helsinki. The study was approved by the Com-
mittee on Human Research Publication and Ethics of the School
of Medical Science of the Kwame Nkrumah University of Sci-
ence and Technology, Kumasi, Ghana.
RESULTS
More than 4 years after initial recruitment, 730 (82.3%) of the
887 children who had completed the original IPTi trial could be
included. Baseline characteristics were similar in both study
arms (Table 1). In total, 45 (6.2%) children had uncomplicated
malaria and 246 (33.7%) had P. falciparum parasitemia, without
signiﬁcant differences between the treatment arms.
Atthe ageof2years,PfLIgGlevelsweresigniﬁcantlyhigherin
children of the placebo group than in those of the SP group
(median, 32.3 RUs [interquartile range, 13.7–55.8] vs 28.4 RUs
[8.9–51.8], respectively; P 5 .03). Interestingly, at the time of
the current survey, PfLIgG levels were—with borderline
signiﬁcance—still higher in the placebo group (Table 1). The
validity of PfLIgG levels as a proxy measure for the number of
malaria episodes during the nonobservation period could be
demonstrated by the positive correlation between PfLIgG levels
and the malaria incidence rates during the 21-month observa-
tion period, showing a similar pattern in each of the study arms
(Figure 1A). Accordingly, the individual Pf LIgG level at the age
of 24 months and that at the time of the current survey showed
a slight but signiﬁcant positive correlation, despite the long time
interval between the 2 measurements (Figure 1B). It is note-
worthy that the risk of parasite positivity at the time of the
survey increased markedly with each measured episode of par-
asitemia during the ﬁrst 2 years of life. This effect was approx-
imately linear with an odds ratio of 1.28 (95% conﬁdence
interval, 1.20–1.36; P , .001) for each additional episode of
parasitemia, independent of SP treatment.
Prevalences of outpatient visits, hospital admissions, and
anemia were not signiﬁcantly different between the SP and
placebo arms, possibly due to a low power in those variables
with rare events. Since the end of the original trial, 5 deaths were
reported in the study population, 2 in the placebo arm and 3 in
the SP arm. Verbal autopsies were performed during visits to
families of the deceased children. Four deaths occurred within 5
months after the last active follow-up and 1 in a child 4 years of
age.Two deaths, 1 in eachstudy arm,wereassumedtoberelated
to severe malaria; 1 death resembled an acute renal failure of
unknown origin; and the remaining 2 deaths were thought to be
caused by typhoid fever. No evidence for Stevens-Johnson
syndrome, known to be a rare serious adverse event of SP, was
recorded.
DISCUSSION
In the present survey, which was performed almost 3 years after
the last dose of SP had been given to participants in a clinical
trial of IPTi, there were no differences in the malariometric
measures, morbidity, or mortality between the 2 study groups.
This ﬁnding supports the assumption of the absence of a re-
bound effect, but cross-sectional surveys only depict in-
formation at a single point in time, which is clearly inferior to
longitudinalstudies.Therefore,PfLIgGlevelwasusedasaproxy
measure for malaria episodes during the nonobservation period
[11, 12]. At the end of the original IPTi trial, when participants
were24monthsofage,PfLIgGlevelsweresigniﬁcantlyhigherin
the placebo group than in the SP group, most likely due to the
higher malaria incidence rate in the unprotected placebo arm.
Unexpectedly, PfLIgG levels still tended to be higher in children
of the placebo arm at the time of the current survey. Assuming
similar malaria exposure risks in the 2 arms due to environ-
mental factors, there are 3 main interpretations for this obser-
vation: The lower PfLIgG level in the SP arm may indicate that
(1) a rebound phenomenon with an inhibition of the de-
velopment of immune responses during and/or after IPTi oc-
curred, (2) malaria episodes were less frequent in the SP arm
Long-term Effects of SP-IPTi d JID 2010:203 (15 February) d 557since the end of the clinical trial, or (3) PfLIgG titers have not
yet equalized in both study arms, leading to a remaining im-
balance of Pf LIgG levels 2 years after the end of the clinical trial.
Notably, a selection or reporting bias is unlikely, since all data
were derived from a randomized trial and the laboratory per-
sonnel measuring PfLIgG levelswere blinded to treatmentarms.
First, the possibility that SP treatment could have exhibited
immunosuppressive effects is conceivable, but unlikely, and
such an effect on P. falciparum lysate responses has not been
reported so far. Moreover, a review of studies assessing the
immune responses after vaccination in combination with SP
therapy reported no evidence of relevant differences [13]. In-
terestingly, antibody responses to single erythrocytic-stage
P. falciparum antigens in infants in Mozambique did not sig-
niﬁcantly differ between children receiving IPTi with SP and
those receiving placebo at any time point measured, with the
Table 1. Characteristics and Outcomes of Study Participants at Follow-up
Placebo (n 5 350) SP (n 5 380) P
a
Characteristics
Sex
Male
Female
183 (52.3)
167 (47.7)
192 (50.5)
188 (49.5)
.64
Age, months, mean 6 SD 53.1 6 3.7 52.8 6 3.8 .37
b-Globin genotype
b
HbAA
HbAS
HbSS
HbAC
HbCC
HbSC
Missing data
258 (73.7)
39 (11.1)
1 (.3)
34 (9.7)
1 (.3)
4 (1.1)
13 (3.7)
275 (72.4)
44 (11.6)
1 (.3)
45 (11.8)
1 (.3)
4 (1.1)
10 (2.6)
.96
Absent at follow up
Moved
Withdrawn
Lost to follow-up
Died
51 (57.3)
16 (18.0)
20 (22.5)
2 (2.3)
38 (55.9)
14 (20.6)
13 (19.0)
3 (4.3)
.82
Outcomes
Uncomplicated malaria
c
Yes
No
Missing data
18 (5.1)
319 (91.1)
13 (3.7)
27 (7.1)
337 (88.7)
16 (4.2)
.50
Parasitemia
Positive
Negative
Missing data
120 (34.3)
217 (62.0)
13 (3.7)
126 (33.2)
238 (62.6)
16 (4.2)
.91
Total PfLIgG level, RUs, median (IQR)
Missing data
22.2 (9.3-38.5)
12 (3.4)
19.1 (6.8-34.5)
9 (2.4)
,.05
Hb level, g/dL, mean 6 SD 10.3 6 1.6 10.3 6 1.5 .77
Anemia
Moderate anemia (,7.5 g/dL)
Severe anemia (,5.0 g/dL)
10 (2.9)
0
11 (2.9)
2 (.5)
.98
.39
Outpatient visits
d
Yes, many times
Yes, sometimes
Yes, once in a while
No
Missing data
119 (34.0)
141 (40.3)
71 (20.3)
18 (5.1)
1 (.3)
120 (31.6)
159 (41.8)
83 (21.8)
18 (4.7)
0
.77
Hospital admissions
d
No
Yes, once
Yes, more than once
Yes, frequency unknown
277 (79.1)
47 (13.4)
23 (6.6)
3 (.9)
305 (80.3)
38 (10.0)
34 (9.0)
3 (.8)
.36
NOTE. Data are no. (%) of participants, unless otherwise indicated. Hb, hemoglobin; IQR, interquartile range; PfLIgG, anti-Plasmodium falciparum lysate IgG
antibody; RUs, relative units; SD, standard deviation; SP, sulfadoxine-pyrimethamine.
a Determined using Wilcoxon rank-sum test or v
2 test. P values ,.05 were considered signiﬁcant.
b b-Globin genotype was determined by polymerase chain reaction.
c An episode of malaria was deﬁned as fever (axillary temperature of >38.0C or fever during the preceding 48 h reported by caretakers without being asked
accompanied by asexual P. falciparum parasite load of .500/lL.
d Frequencies since last follow-up of core study. Information obtained by interviewing participants’ mothers and caretakers and reviewing medical records.
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tigen 1 and/or merozoite surface protein 1, which were even
higher in the SP-treated group [14].
Second, during the observation period there was no further
protective efﬁcacy after elimination of SP from the children’s
blood, as shown previously [7]. Consequently, long-lasting
protective effects beyond posttreatment prophylaxis are not
expected, although a sustained protection has been described
elsewhere [5]. This is in line with ﬁndings from a study in
northern Tanzania that tested different antimalarials for IPTi
and showed that the beneﬁts of IPTi are directly dependent on
the pharmacodynamics of the drugs involved [15]. However, it
cannot be excluded that small long-term effects on the risk of
parasitemia exist, which could not have been observed clinically.
Third, it has been demonstrated before that PfLIgG levels in the
second year of life are dependent on the frequency of preceding
infections in both study arms [11]. In that study, PfLIgG levels
were generally lower in children protected by SP. Furthermore,
Figure 1. Correlation of anti–Plasmodium falciparum lysate IgG antibody (PfLIgG) levels and malaria incidence rate. A, Correlation of PfLIgG levels at
the age of 24 months with the documented malaria incidence rates during the 21-month observation period. There is a similar pattern in children formerly
treated with placebo or sulfadoxine-pyrimethamine (SP). B, Correlation between individual PfLIgG levels at age 24 months and PfLIgG levels at the time of
the survey, plotted by treatment. Despite the long time interval between the 2 measurements, there is a positive correlation with a similar pattern in both
study arms. PfLIgG level was measured by enzyme-linked immunosorbent assay and expressed in relative units (RUs) as described previously [11]. PYAR,
person-years at risk.
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ren’shomevillagesandthiscorrelationwasmorepronouncedin
children in the SP arm than in those from the placebo arm,
indicating a higher reduction of overall parasitic exposure in
more intense transmission settings [16].
One interesting observation, that each parasitemia episode
during the ﬁrst 2 years of life increases the risk of parasite
positivity at time of the survey, was independent of former SP
treatment. This corresponds to the positive correlation of in-
dividual PfLIgG level, which indicates that children with high
levels of antibodies in the past also tend to have higher antibody
levels years later. Apart from indirectly supporting the hypoth-
esis that immune responses were not selectively inhibited by SP,
these results show that individual susceptibilities to P. falcipa-
rum are sustainable over years. This is in line with earlier ob-
servations that a small percentage of the population suffers the
majority of infections [17]. Identifying this high-risk group is
essential to successfully targeting future malaria control inter-
ventions. Meanwhile, by presumptively treating all infants, IPTi
is not very selective, but it is cheap, safe, and effective.
In summary, it seems appropriate to use PfLIgG level as
a proxy measure for the number of malaria episodes during the
nonobservation period. Accordingly,themostlikely explanation
for lower Pf LIgG levels in children of the SP arm seems to be
a lower overall exposure to parasitic antigens in comparison to
children who received placebo. Taken together, these ﬁndings
argue against long-term negative rebound effects after SP-IPTi
in areas of high malaria transmission.
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